This is a critical study in the Ozempic lawsuit because the label does not warn of this side effect
The 11.3% discontinuation in TRIUMPH-1 suggests real-world tolerability may be better than TRIUMPH-4's 18.2% initially implied
its up to the FDA, and right now, these specific peptides sit outside it. The biggest risk to this potential pathway, Robinson explains, is reporting of adverse events, which the FDA describes as any undesirable experience associated with the use of a medical product in a patient. Should an adverse event happen, Robinson says it could negatively impact or delay the rulemaking process. As the FDA pointed out in their official meeting recommendation to keep the peptides under their current restrictions, these peptides simply dont have adequate clinical data behind them
Others In addition to the above compounds, many other natural medicines potentially protect the myocardium by enhancing the GSH antioxidant system
For example, a number of large-scale clinical trials have demonstrated that GLP-1RA could reduce the risk of cardiovascular events, which has been well reviewed in elsewhere (83, 84) and we will not further discuss here
